Search results for " Ly"

showing 10 items of 2487 documents

Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation fo…

2005

Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted. Therefore, we have designed a prospective phase II trial in CML, which, for the first time, evaluated the feasibility and safety of molecular end points as surrogate markers to guide through a stratified treatment algorithm within a multicenter trial. Patients and Methods As a clinical model, we adopted minimal residual disease (MRD) found in relapse after allogeneic stem cell transplantation (SCT) in CML. For…

AdultOncologyCancer Researchmedicine.medical_specialtyTime FactorsMaximum Tolerated Dosemedicine.drug_classFusion Proteins bcr-ablGraft vs Host DiseaseAntineoplastic AgentsPolymerase Chain ReactionPiperazinesTyrosine-kinase inhibitorMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesMulticenter trialInternal medicinemedicineHumansTransplantation HomologousProspective Studiesbusiness.industryRemission InductionImatinibProtein-Tyrosine Kinasesmedicine.diseaseMinimal residual diseaseTransplantationPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesImmunologyImatinib MesylateFeasibility StudiesbusinessStem Cell Transplantationmedicine.drugChronic myelogenous leukemiaJournal of Clinical Oncology
researchProduct

Is extracapsular nodal extension in sentinel nodes a predictor for nonsentinel metastasis and is there an impact on survival parameters?-A retrospect…

2016

The Z0011 trial has fundamentally changed axillary management in breast cancer patients. However, some important questions remain, like the role of extracapsular nodal extension (ENE) in positive sentinel nodes and the need for further axillary treatment. In this retrospective cohort study, we reviewed and analyzed data from 342 clinically node negative (cN0) breast cancer patients with a positive sentinel node and subsequent axillary lymph node dissection (ALND) from the BRENDA data base. The 104 (30.4%) ENE positive patients had a significantly higher proportion of ≥3 positive axillary lymph nodes (65.0%) compared to ENE negative patients with a positive sentinel node (21.4%). Likewise, E…

AdultOncologymedicine.medical_specialtyAxillary lymph nodesBreast NeoplasmsMetastasis03 medical and health sciences0302 clinical medicineBreast cancerPredictive Value of TestsInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineLymph nodeAgedRetrospective StudiesAged 80 and overUnivariate analysisSentinel Lymph Node Biopsybusiness.industryAxillary Lymph Node DissectionRetrospective cohort studyMiddle AgedSentinel nodemedicine.diseaseSurvival Analysismedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisFemaleSurgerySentinel Lymph NodebusinessThe Breast Journal
researchProduct

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid…

2008

Abstract Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 mont…

AdultOncologymedicine.medical_specialtyTime FactorsAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classImmunologyimatinib CML interferon-alphaSalvage therapyBlastic PhaseBiochemistryPiperazinesTyrosine-kinase inhibitorhemic and lymphatic diseasesInternal medicinemedicineHumansneoplasmsSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryInterferon-alphaMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseSurgerySurvival RatePyrimidinesTreatment OutcomeImatinib mesylateBenzamidesLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylatebusinessFollow-Up StudiesChronic myelogenous leukemiamedicine.drug
researchProduct

Current results on the use of imatinib mesylate in patients with relapsed philadelphia chromosome positive leukemia after allogeneic or syngeneic hem…

2003

Here, we describe a patient diagnosed with chronic myelogenous leukemia who relapsed after matched unrelated donor SCT. The patient was treated with imatinib mesylate and donor lymphocyte infusions, and achieved a complete molecular remission. Additionally, safety and efficacy of imatinib mesylate in a total of 134 patients from 8 centers who underwent allogeneic or syngeneic stem cell transplantation (SCT) and had a relapse of Philadelphia chromosome positive leukemia was reviewed. Data was compiled from abstracts accepted as oral or poster presentations at the ASH (American Society of Hematology) 2001 and EBMT (European Group for Blood and Marrow Transplantation) 2001 & 2002 meetings and …

AdultOncologymedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationAntineoplastic AgentsHematopoietic stem cell transplantationPolymerase Chain ReactionPiperazinesRecurrenceLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansTransplantation Homologouseducationeducation.field_of_studyHematologybusiness.industryHematopoietic Stem Cell TransplantationGeneral Medicinemedicine.diseaseSurgerySyngeneic stem cell transplantationTransplantationTransplantation IsogeneicLeukemiaPyrimidinesTreatment OutcomeImatinib mesylateBenzamidesImatinib MesylateFemalebusinessChronic myelogenous leukemiaThe Keio Journal of Medicine
researchProduct

Solid variant of mammary "adenoid cystic carcinoma with basaloid features" merging with "small cell carcinoma"

2005

We describe a rare case of a solid variant of a mammary adenoid cystic carcinoma with basaloid features (sbACC) and its coexistence with a "small cell" carcinoma (SCC), identified and confirmed by histological and immunohistochemical observations: the absence of glandular structures and PAS-positive globules, positivity for neuroendocrine markers (NSE, synaptophysin and chromogranin), and negativity for 34betaE12 and SMA actin were the aspects suggesting the presence of SCC. Furthermore, positivity for CD10 was found both in sbA CC and in SCC, supporting the hypothesis that the two components share the same histogenetic myoepithelial origin and represent an example of dedifferentiation alon…

AdultPathologymedicine.medical_specialtyAdenoid cystic carcinoma2734Breast NeoplasmsBiologyHistogenesisSettore MED/08 - Anatomia PatologicaMastectomy SegmentalSmall-cell carcinomaPathology and Forensic MedicineNeoplasms Multiple PrimaryBiomarkers TumormedicineCarcinomaHumansBreastCarcinoma Small CellneoplasmsSmall cell carcinomaMyoepithelial cellChromogranin ABasaloid adenoid cystic carcinomaCell BiologyPeriodic Acid-Schiff Reactionmedicine.diseaseCarcinoma Adenoid CysticImmunohistochemistrystomatognathic diseasesSettore MED/18 - Chirurgia GeneraleCarcinoma Basal CellChemotherapy AdjuvantAxillaSynaptophysinbiology.proteinLymph Node ExcisionImmunohistochemistryFemaleBasaloid adenoid cystic carcinoma; Breast; Small cell carcinoma; Adult; Axilla; Biomarkers Tumor; Breast Neoplasms; Carcinoma Adenoid Cystic; Carcinoma Basal Cell; Carcinoma Small Cell; Chemotherapy Adjuvant; Female; Humans; Immunohistochemistry; Lymph Node Excision; Mastectomy Segmental; Neoplasms Multiple Primary; Periodic Acid-Schiff Reaction; 2734Breast NeoplasmHuman
researchProduct

Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population‐bas…

2021

Objective: Investigate all-cause and cause-specific late mortality after childhood acute lymphoblastic leukemia (ALL) in a population-based Nordic cohort. Methods: From the cancer registries of Denmark, Finland, and Sweden, we identified 3765 five-year survivors of ALL, diagnosed before age 20 during 1971–2008. For each survivor, up to five matched comparison subjects were randomly selected from the general population (n = 18,323). Causes of death were classified as relapse related, health related, and external. Late mortality was evaluated by cumulative incidences of death from 5-year survival date. Mortality hazard ratios (HR) were evaluated with Cox proportional models. Results: Among th…

AdultPediatricsmedicine.medical_specialtycause-specific mortalityDenmarkPopulationlong-term follow-upacute lymphoblastic leukemiaDECADESCohort StudiesYoung AdultCancer SurvivorsSurvivorship curvechildhood cancerHumansMedicineCumulative incidenceeducationChildhood Acute Lymphoblastic LeukemiaFinlandSwedeneducation.field_of_studyOvertreatmentbusiness.industryHazard ratioDEATHCancer5-YEAR SURVIVORSHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCANCERConfidence intervalREDUCTIONOncologylate mortalityPediatrics Perinatology and Child HealthCohortFOLLOW-UPbusinesssurvivorshipPediatric Blood & Cancer
researchProduct

Obstructive sleep apnoea in adult patients post-tonsillectomy

2021

Background: The impact of removing the upper airway lymphoid tissue and in particular, tonsillectomy, in adults with OSA has not been demonstrated in large populations. Aims: To compare the severity of OSA and the prevalence of cardiovascular, metabolic and respiratory co-morbidities between patients with OSA who had undergone previous tonsillectomy and those who had not. Methods: The 19,711 participants in this study came from the European sleep apnea database (ESADA) which comprises data from unselected adult patients aged 18–80 years with a history of symptoms suggestive of OSA referred to sleep centers throughout Europe. Results: There were no differences between the two groups in terms…

AdultPediatricsmedicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]ESADALymphoid tissue overgrowthSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesSleep apnoea0302 clinical medicinemedicineHumansMass indexRespiratory systemTonsillectomySleep Apnea ObstructiveAdult patientsbusiness.industrySleep apneaGeneral MedicineESADA ; Lymphoid tissue overgrowth ; Sleep apnoea ; Tonsillectomy.medicine.diseaseSleep in non-human animalsrespiratory tract diseasesTonsillectomy[SDV] Life Sciences [q-bio]Europe030228 respiratory systemDiabetes Mellitus Type 2Lower prevalenceTonsillectomy.AirwaybusinessSleep030217 neurology & neurosurgery
researchProduct

Whole-body MRI radiomics model to predict relapsed/refractory Hodgkin Lymphoma: A preliminary study.

2022

Purpose A strong prognostic score that enables a stratification of newly diagnosed Hodgkin Lymphoma (HL) to identify patients at high risk of refractory/relapsed disease is still needed. Our aim was to investigate the potential value of a radiomics analysis pipeline from whole-body MRI (WB-MRI) exams for clinical outcome prediction in patients with Hodgkin Lymphoma (HL). Materials and methods Index lesions from baseline WB-MRIs of 40 patients (22 females; mean age 31.7 ± 11.4 years) with newly diagnosed HL treated by ABVD chemotherapy regimen were manually segmented on T1-weighted, STIR, and DWI images for texture analysis feature extraction. A machine learning approach based on the Extra T…

AdultPositron emission tomographymedicine.medical_specialtyWhole body mriBiomedical EngineeringBiophysicsVinblastineBleomycinYoung AdultRefractoryRadiomicsPositron Emission Tomography Computed TomographyMachine learningAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRadiology Nuclear Medicine and imagingMagnetic resonance imaging Positron emission tomography Machine learning Texture analysis Hodgkin Lymphomamedicine.diagnostic_testHodgkin Lymphomabusiness.industryMagnetic resonance imagingMetabolic tumor volumeHodgkin DiseaseMagnetic Resonance ImagingDacarbazineTexture analysisPositron emission tomographyDoxorubicinRelapsed refractoryHodgkin lymphomaFemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMagnetic resonance imaging
researchProduct

Complications of Poly Implant Prothèse breast implants: the current discussion

2013

Against the background of the current discussion about Poly Implant Prothèse (PIP, Seyne-sur-mer, France) breast implants, we want to present a case demonstrating the complications such as implant rupture, silicone dissemination and level III silicone lymphadenopathy. A 29-year-old woman with cosmetic breast augmentation with PIP implants 5 years previously showed a sensitive swelling in her right axilla and neck region. All tests to detect an infectious or lymphomatous lymphadenopathy were negative. After ultrasound and MRI, rupture of the right implant was assumed and multiple pathologically enlarged lymph nodes up to supraclavicular region were shown. An excision biopsy of one axillary l…

AdultReoperationmedicine.medical_specialtyAxillary lymph nodesBiopsyBreast ImplantsBiomedical EngineeringProsthesis DesignSilicone Gelschemistry.chemical_compoundSiliconeBiopsymedicineHumansBreast ImplantationLymphatic DiseasesBreast augmentationLymph nodeDevice Removalmedicine.diagnostic_testbusiness.industryForeign-Body ReactionGeneral MedicineProsthesis FailureSurgeryAxillaTreatment Outcomemedicine.anatomical_structurechemistryAxillaLymph Node ExcisionFemaleSurgeryLymph NodesLymphImplantbusinessExpert Review of Medical Devices
researchProduct

Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprot…

1992

SUMMARYAutoantibodies against the human asialoglycoprotein receptor (ASGPR) occur in the sera orpaticnts with autoimmune liver disorders. Live-nfiltrating T cell clones that specifically recognize the ASGPR have been described in patients with autoimmune chronic active hepatitis (A-AH) and primary biliary cirrhosis (PBC). Recently, we have shown that peripheral blood mononuclcar cells (PBMC) from patients with A-AH or PBC but not chronic viral hepatitis secreted ant-SGPR antibodies in vitro. In this study we characterized the influence of live-nfiltrating T cells on the secretion of ASGP-pecific autoantibodies by autologous B cells in cell culture supernatants. T cell clones from liver biop…

AdultT cellCD8 AntigensImmunologyAsialoglycoprotein ReceptorPeripheral blood mononuclear cellAutoimmune DiseasesmedicineImmunology and AllergyHumansReceptors ImmunologicCells CulturedAutoantibodiesHepatitis ChronicbiologyAutoantibodyT lymphocyteT-Lymphocytes Helper-InducerMiddle Agedmedicine.anatomical_structureLiverCell cultureImmunologyCD4 Antigensbiology.proteinAsialoglycoprotein receptorFemaleAntibodyCD8Research ArticleClinical and experimental immunology
researchProduct